论文部分内容阅读
目的：比较 MNP方案（丝裂霉素、去甲长春碱、顺铂）与 MVP方案（丝裂霉素、长春地辛、顺铂）治疗晚期非小细胞肺癌的疗效。方法： 83例晚期非小细胞肺癌患者接受 MNP与 MVP方案化疗。病人一般特征经χ 2检验和 t检验，两组具有可比性（ P >0.05）。 MNP方案 40例， MVP方案 43例。结果： MNP组 CR 3例， PR 15例， NC 20例， PD 2例，有效率为 45.0％；中位缓解期 8.0月，中位生存期 10.5月， 1年生存率 42.5％。 MVP组 PR 14例， NC 20例， PD 9例，有效率为 32.6％；中位缓解期 6.8月，中位生存期 8.1月， 1年生存率 27.9％。两组有效率无显著性差异 (P=0.06975， Radit分析 )， MNP组生存期优于 MVP组，但无统计学差异（ P=0.1516， Log rank检验）。血液学毒性发生率 MNP组高于 MVP组，其中白细胞减少两组差异有统计学意义；神经毒性 MVP组高于 MNP组；静脉炎、口腔炎和发热 MNP组高于 MVP组；但差异均无统计学意义（ P >0.05，秩和检验）；其他毒性相近。结论：用 MNP方案治疗晚期非小细胞肺癌效率较高， MNP方案可作为一线治疗方案，但其是否优于常用的 MVP方案，需进一步随机研究。
OBJECTIVE: To compare the efficacy of MNP regimen (mitomycin, norepinephrine, cisplatin) and MVP regimen (mitomycin, vindesine, cisplatin) in the treatment of advanced non-small cell lung cancer. Methods: Eighty-three patients with advanced non-small cell lung cancer undergoing MNP and MVP regimen chemotherapy. The general characteristics of patients by χ 2 test and t test, the two groups were comparable (P> 0.05). MNP program in 40 cases, MVP program in 43 cases. Results: In MNP group, there were 3 cases of CR, 15 cases of PR, 20 cases of NC and 2 cases of PD. The effective rate was 45.0%. The median remission was 8.0 months. The median survival time was 10.5 months. The 1-year survival rate was 42.5%. In MVP group, there were 14 cases of PR, 20 cases of NC and 9 cases of PD with an effective rate of 32.6%. The median remission was 6.8 months. The median survival time was 8.1 months. The 1-year survival rate was 27.9%. There was no significant difference between the two groups (P = 0.06975, Radit analysis). The MNP group had better survival than the MVP group (P = 0.1516, Log-rank test). The incidence of hematological toxicity in MNP group was higher than that in MVP group, among which the leukopenia was significantly different between the two groups; neurotoxicity MVP group was higher than MNP group; phlebitis, stomatitis and fever MNP group were higher than MVP group; Statistical significance (P> 0.05, rank sum test); other toxic similar. CONCLUSION: The MNP regimen is superior in the treatment of advanced non-small cell lung cancer. The MNP regimen is a first-line regimen, but whether it is superior to the usual MVP regimen requires further randomized studies.